Hodgkin Lymphoma - Relapsed/Refractory
Sort by:
Penn Medicine's 2023 Updates in Care of the Hematologic Malignancies Patient
Updates in Management of Hodgkin Lymphoma
FEATURING
Jakub Svoboda
- 123 views
- February 14, 2023
Indy Hematology Review
Targeting and Treating Indolent, Mantle Cell, and Hodgkin Lymphoma
FEATURING
Nancy Bartlett
- 37 views
- January 25, 2023
Indy Hematology Review
2022 Management of Long-Term Survivors of Hematologic Malignancies
FEATURING
Sandra Garofalo
- 26 views
- January 20, 2023
Indy Hematology Review
Targeting and Treating Indolent Lymphomas and Hodgkin Lymphoma
FEATURING
Nancy Bartlett
- 81 views
- January 19, 2023
ASH 2022 Conference Coverage
ASH 2022 Results of the Phase II Radvax Trial: Low-Dose RT With Nivo in Patients With R/R Hodgkin Lymphoma
FEATURING
Michael LaRiviere
- 50 views
- December 16, 2022
PrecisCa
What Is Nodular Lymphocyte Predominant Hodgkin Lymphoma and How Do You Treat It?
FEATURING
Jeremy Abramson
- 49 views
- December 15, 2022
- 1
SOHO Highlights: State of the Art and Next Questions
SOHO Highlights - State of the Art & Next Questions: Hodgkin Lymphoma
FEATURING
Nancy Bartlett
- 351 views
- December 6, 2022
- 1
SOHO 4th Italian Conference
SOHO Italy 2022: How I Manage Hodgkin Lymphoma in the USA
FEATURING
Amanda Cashen
- 125 views
- November 30, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Long-Term Outcomes After Haplo-SCT for Hematologic Malignancies
FEATURING
Supawee Saengboon
- 142 views
- October 17, 2022
- 1
SOHO 2022 Tenth Annual Meeting
SOHO 2022 Next Questions: Hodgkin Lymphoma
FEATURING
Nancy Bartlett
- 248 views
- October 14, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Camidanlumab Tesirine - Updated Efficacy and Safety in Patients With R/R cHL
FEATURING
Alex Herrera
- 28 views
- October 14, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Treating Hodgkin Lymphoma After Brentuximab Vedotin and Anti-PD1 Failure
FEATURING
Alex Herrera
- 150 views
- October 14, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Sequencing Novel Agents in Frontline and Second-Line Treatment of Hodgkin Lymphoma
FEATURING
Alison Moskowitz
- 236 views
- October 14, 2022
- 1
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Basis for Targeting the Microenvironment in Hodgkin Lymphoma
FEATURING
Christian Steidl
- 80 views
- October 13, 2022
SOHO 2022 Tenth Annual Meeting
SOHO 2022: CAR T-Cell Therapy in Hodgkin Lymphoma
FEATURING
Carlos Ramos
- 24 views
- October 13, 2022
University of Colorado Department of Medicine
Immunotherapy in Lymphomas: The Present and the Future
FEATURING
Manali Kamdar
- 860 views
- September 7, 2022
- 6
Indy Hematology Review
State of the Art: Current and Emerging Treatment of Hodgkin’s Lymphoma
FEATURING
Ranjana Advani
- 45 views
- September 6, 2022
UChicago Medicine
Update on Immunotherapy Efforts in cHL and DLBCL
FEATURING
Justin Kline
- 222 views
- August 19, 2022
- 1
19th Annual International Ultmann Chicago Lymphoma Symposium
Treatment of 1st Relapsed Classical Hodgkin Lymphoma
FEATURING
Vaishalee Kenkre
- 163 views
- July 11, 2022
19th Annual International Ultmann Chicago Lymphoma Symposium
Impact of the Immune Landscape on Hodgkin Lymphoma Prognosis and Treatment
FEATURING
Christian Steidl
- 112 views
- July 11, 2022
- 1
